The global scoring method improved inter-laboratory consistency but also led to a notable increase in cases classified as intermediate at both centers This has been captured in the 2022 Swedish clinical breast cancer guidelines recommending molecular profiling test for patients with Grade II, global Ki67 intermediate score, T1c / T2 breast cancer. The gene discussed is MKI67; the disease is breast cancer.